We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.
- Authors
Koul, Dimpy; Shen, Ruijun; Kim, Yong-Wan; Kondo, Yasuko; Lu, Yiling; Bankson, Jim; Ronen, Sabrina M; Kirkpatrick, D Lynn; Powis, Garth; Yung, W K Alfred
- Abstract
The phosphatidylinositol-3-kinase (PI3K)/Akt oncogenic pathway is critical in glioblastomas. Loss of PTEN, a negative regulator of the PI3K pathway or activated PI3K/Akt pathway that drive increased proliferation, survival, neovascularization, glycolysis, and invasion is found in 70%-80% of malignant gliomas. Thus, PI3K is an attractive therapeutic target for malignant glioma. We report that a new irreversible PI3K inhibitor, PX-866, shows potent inhibitory effects on the PI3K/Akt signaling pathway in glioblastoma. PX-866 did not induce any apoptosis in glioma cells; however, an increase in autophagy was observed. PX-866 inhibited the invasive and angiogenic capabilities of cultured glioblastoma cells. In vivo, PX-866 inhibited subcutaneous tumor growth and increased the median survival time of animals with intracranial tumors. We also assessed the potential of proton magnetic resonance spectroscopy (MRS) as a noninvasive method to monitor response to PX-866. Our findings show that PX-866 treatment causes a drop in the MRS-detectable choline-to-NAA, ratio and identify this partial normalization of the tumor metabolic profile as a biomarker of molecular drug action. Our studies affirm that the PI3K pathway is a highly specific molecular target for therapies for glioblastoma and other cancers with aberrant PI3K/PTEN expression.
- Publication
Neuro-oncology, 2010, Vol 12, Issue 6, p559
- ISSN
1523-5866
- Publication type
Journal Article
- DOI
10.1093/neuonc/nop058